“Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials”, J of Skin, vol. 10, no. 2, p. s757, Mar. 2026, doi: 10.25251/v6wwxw80.